Repligen (RGEN) Stock Forecast & Price Target

Repligen is positioned for a favorable recovery because its underlying bioprocessing demand remains healthy, with consumables up about 20%, chromatography up 50%, and proteins up 40%, supporting continued double-digit organic growth despite softer filtration equipment sales. Its Q3 results showed improving momentum in capital equipment orders, which rose mid-teens year over year to the highest level in five years, while China grew more than 40% with record orders and EMEA remained strong above 20%. Management’s FY26 organic growth guidance of 12% to 13% and adjusted operating income guidance of $135 million to $139 million suggest improving leverage, while the stock’s valuation still appears reasonable relative to its premium growth profile and history.

Repligen is facing a weak fundamental setup because the expected reshoring-driven rebound in bioprocess equipment demand has not materialized, and post-COVID industry demand has remained soft, with some peers seeing 20%+ annual declines from 2023 to 2025. With equipment representing about 25% of sales and fluid management and downstream systems under pressure, the company is exposed to a slow recovery in routine orders that may not arrive until no later than 2027, while multiple compression risk increases if growth and profitability miss expectations. Competitive threats to its ATF products, which comprise nearly 20% of sales, and concentration in risky cell/gene therapy and mRNA modalities further weaken the outlook.